Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA first-quarter 1988 NME approvals

Executive Summary

FDA Commissioner Young has stated publicly that "a substantial number" of approvals are likely to occur in the first three months of 1988 ("The Pink Sheet" Jan. 11, p. 10). At a Jan. 19 analysts meeting in New York, Warner-Lambert Chairman Joe Williams said that, based on a personal conversation with the commissioner, he believes the agency could approve 11 NMEs by March 31. Young has publicly committed the agency to try to spread out NDA approvals throughout the calendar year.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS013062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel